• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Rivaroxaban and warfarin have similar safety and efficacy in mild atrial fibrillation-related ischemic stroke

byShayna BejaimalandAnees Daud
September 15, 2017
in Cardiology, Chronic Disease, Emergency, Gastroenterology, Imaging and Intervention, Neurology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this randomized controlled trial, rivaroxaban and warfarin were similar in safety and efficacy when used to prevent early recurrence of stroke in patients with atrial fibrillation (AF)-related acute ischemic stroke.

2. Rivaroxaban was associated with reduced hospital length of stay.

Evidence Rating Level: 2 (Good)

Study Rundown: Patients that have atrial fibrillation (AF)-related ischemic strokes are at high risk of recurrent ischemic stroke and intracranial hemorrhage. However the optimal oral anticoagulation medication in this regard is not clear. This randomized, multicenter, open-label, blinded endpoint evaluation trial aimed to test whether rivaroxaban or warfarin is safer and more effective for preventing early recurrent stroke in patients with AF-related acute ischemic stroke.

Groups randomized to rivaroxaban or warfarin showed no differences in the primary composite endpoint of new ischemic lesion or new intracranial hemorrhage seen on MRI at 4 weeks. Each group only had 1 clinical ischemic stroke. All intracranial hemorrhages were asymptomatic and were deemed to be hemorrhagic transformations. Length of stay in hospital, however, was shorter for those randomized to rivaroxaban, likely owing to time required for warfarin uptitration. Strengths of this study included a randomized design. Limitations of this study included its low event rate and open-label design. Also, only 47% of those randomized to warfarin were within therapeutic anticoagulation range at 4 weeks, this study cannot be applied to individuals who achieve higher time in therapeutic window on warfarin.

Click to read the study, published in JAMA Neurology

RELATED REPORTS

Ablation may reduce stroke risk, death, heart failure hospitalization in patients with atrial fibrillation

The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave

Impaired lipoprotein cholesterol ratio is associated with cognitive impairment in patients with stroke

Relevant Reading: Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation Effect of Anticoagulation and Its Timing: The RAF Study

In-Depth [randomized trial]: This randomized, multicenter, open-label, blinded endpoint evaluation trial was conducted from April 2014 to December 2015 at 14 academic medical centres in South Korea. Patients included had mild AF-related stroke in the previous 5 days and were deemed suitable for early anticoagulation. Suitability was determined by diffusion-weighted image analysis of the acute ischemic lesion. Exclusion criteria included: significant hemorrhagic transformation, mechanical heart valve, stroke caused by small vessel occlusion, severe renal impairment and high risk of intracranial or systemic bleeding. Patients were randomized 1:1 to rivaroxaban (10 mg/day for 5 days then 15-20 mg per day for 4 weeks) or warfarin (with target INR between 2.0-3.0). Patients and responsible physicians were not blinded to the assignment, however adjudicators and assessors of the MRIs were blinded. The primary outcome was a composite of new ischemic lesion or new intracranial hemorrhage on results of follow-up MRI at 4 weeks. Secondary outcomes included individual components of the primary outcome as well as hospital length of stay. Outcomes were assessed in a modified intention-to-treat analysis. Statistical analysis included χ2 testing and Poisson regression.

Of 183 patients included in the primary analysis, 95 were in the rivaroxaban group and 88 in the warfarin group. At 4 weeks only 47% of patients in the warfarin group had achieved INR target between 2.0-3.0. For the primary composite outcome there were no significant difference between the rivaroxaban and warfarin groups (47 [49.5%] vs. 48 [54.5%]; relative risk 0.91; 95% CI 0.69-1.20, p = 0.49). There was also no significant difference for the individual components of new ischemic lesion or intracranial hemorrhage between groups. There was only 1 clinical ischemic stroke for each group. Hospital length of stay was reduced in the rivaroxaban group (median 4.0 days vs. 6.0 days; p < 0.001).

Image: CC/Wiki

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: anticoagulantatrial fibrillationischemic stroke
Previous Post

Sentinel lymph node dissection not inferior to complete axillary lymph node dissection for women with nodal involvement of breast cancer

Next Post

2 Minute Medicine Rewind September 18, 2017

RelatedReports

Atrial fibrillation-specific management increases days alive and out of hospital
Cardiology

Ablation may reduce stroke risk, death, heart failure hospitalization in patients with atrial fibrillation

July 4, 2025
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Celebrity diagnoses spur screenings, athlete mental-health push, reality-TV heart lesson, and a sitcom PSA wave

July 2, 2025
Quick Take: Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial
Chronic Disease

Impaired lipoprotein cholesterol ratio is associated with cognitive impairment in patients with stroke

June 4, 2025
Stroke expansion following intra-arterial therapy may explain worse outcomes
Emergency

Delayed alteplase has clinical benefits in posterior circulation stroke outcomes

May 30, 2025
Next Post
Oral contraceptive pills associated with reduction in ovarian cancer incidence

2 Minute Medicine Rewind September 18, 2017

Computed tomography improves diagnostic certainty in the emergency department

Emergency Departments more likely to transfer injured children on Medicaid

Adalimumab use results in high clinical response rate in hidradenitis suppurativa

Revenue from new cancer-drugs substantially greater than cost of development

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Oral vancomycin may be effective for pouchitis in inflammatory bowel disease
  • Inebilizumab improves outcome in patients generalized myasthenia gravis
  • Medbridge turns any phone into a motion-capture coach for at-home rehab
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.